Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2272-2281
Open Access | Times Cited: 329

Showing 1-25 of 329 citing articles:

Advances in oral peptide therapeutics
Daniel J. Drucker
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 4, pp. 277-289
Closed Access | Times Cited: 503
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 391
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 243
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 229
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman, Vanita R. Aroda, John B. Buse, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2262-2271
Open Access | Times Cited: 205
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
David J. Brayden, Timothy A. Hill, David P. Fairlie, et al.
Advanced Drug Delivery Reviews (2020) Vol. 157, pp. 2-36
Open Access | Times Cited: 199
Safety of Semaglutide
Mark M. Smits, Daniël H. van Raalte
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 180
Insulin resistance and insulin sensitizing agents
Lucia Mastrototaro, Michael Roden
Metabolism (2021) Vol. 125, pp. 154892-154892
Open Access | Times Cited: 163
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Mansoor Husain, Stephen C. Bain, Ole K. Jeppesen, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 3, pp. 442-451
Open Access | Times Cited: 153
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Giulia Bendotti, Laura Montefusco, Maria Elena Lunati, et al.
Pharmacological Research (2022) Vol. 182, pp. 106320-106320
Closed Access | Times Cited: 152
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans
Journal of Investigative Medicine (2021) Vol. 70, Iss. 1, pp. 5-13
Open Access | Times Cited: 136
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 130
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 111
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Pasquale Mone, Angela Lombardi, Jessica Gambardella, et al.
Diabetes Care (2022) Vol. 45, Iss. 5, pp. 1247-1251
Open Access | Times Cited: 110
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 98
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Chi Kin Wong, Brent A. McLean, Laurie L. Baggio, et al.
Cell Metabolism (2023) Vol. 36, Iss. 1, pp. 130-143.e5
Closed Access | Times Cited: 97
Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
Manoj Kumar Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 3, pp. 521-539
Open Access | Times Cited: 93
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 75
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R. Aroda, Jens Aberle, Lars Bardtrum, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 693-704
Open Access | Times Cited: 62
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Femin Prasad, Riddhita De, Vittal Korann, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 57
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 37
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
Tyler Drake, Adrienne Landsteiner, Lisa Langsetmo, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 5, pp. 618-632
Closed Access | Times Cited: 22
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
Anastas Kick, Khadija M'Rabet‐Bensalah, Flavio Acquistapace, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 623-637
Open Access | Times Cited: 19
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: ThePIONEERprogramme
Tina K. Thethi, Richard E. Pratley, Juris J. Meier
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 8, pp. 1263-1277
Open Access | Times Cited: 100
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
Juris J. Meier
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top